Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association

Circulation, Journal Year: 2020, Volume and Issue: 141(9)

Published: Jan. 29, 2020

The American Heart Association, in conjunction with the National Institutes of Health, annually reports on most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, diet, weight) factors (cholesterol, blood pressure, glucose control) that contribute health. Statistical Update presents latest data a range major clinical circulatory disease conditions (including congenital rhythm disorders, subclinical atherosclerosis, coronary failure, valvular venous peripheral artery disease) associated outcomes quality care, procedures, economic costs).The through its Statistics Committee, continuously monitors evaluates sources stroke United States provide current information available annual Update. 2020 is product full year's worth effort by dedicated volunteer clinicians scientists, committed government professionals, Association staff members. This edition includes monitoring benefits population, metrics assess monitor healthy diets, an enhanced focus social determinants health, global burden further evidence-based approaches changing behaviors, implementation strategies, implications Association's Impact Goals.Each 26 chapters focuses different topic statistics.The represents critical resource for lay public, policy makers, media clinicians, healthcare administrators, researchers, advocates, others seeking best these conditions.

Language: Английский

---

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

European Heart Journal, Journal Year: 2019, Volume and Issue: 41(1), P. 111 - 188

Published: Aug. 31, 2019

The ESC/EAS Guidelines represent the views of ESC and EAS, were produced after careful consideration scientific medical knowledge, evidence available at time their publication.The EAS is not responsible in event any contradiction, discrepancy, and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical judgment, as well determination implementation preventive, diagnostic, strategies; however, do override, way whatsoever, individual responsibility make appropriate accurate decisions each patient's condition consultation with that patient and, where necessary, caregiver.Nor exempt from taking full updated competent order manage case light scientifically accepted data pursuant respective ethical professional obligations.It also professional's verify applicable rules regulations relating drugs devices prescription.

Language: Английский

---

Heart Disease and Stroke Statistics—2021 Update

Circulation, Journal Year: 2021, Volume and Issue: 143(8)

Published: Jan. 27, 2021

The American Heart Association, in conjunction with the National Institutes of Health, annually reports most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, diet, weight) factors (cholesterol, blood pressure, glucose control) that contribute health. Statistical Update presents latest data on a range major clinical circulatory disease conditions (including congenital rhythm disorders, subclinical atherosclerosis, coronary failure, valvular venous peripheral artery disease) associated outcomes quality care, procedures, economic costs).The through its Statistics Committee, continuously monitors evaluates sources stroke United States provide current information available annual Update. 2021 is product full year's worth effort by dedicated volunteer clinicians scientists, committed government professionals, Association staff members. This edition includes monitoring benefits population, an enhanced focus social determinants health, adverse pregnancy outcomes, vascular contributions brain global burden further evidence-based approaches changing disease.Each 27 chapters focuses different topic statistics.The represents critical resource for lay public, policy makers, media clinicians, care administrators, researchers, advocates, others seeking best these conditions.

Language: Английский

---

Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association

Circulation, Journal Year: 2022, Volume and Issue: 145(8)

Published: Jan. 26, 2022

The American Heart Association, in conjunction with the National Institutes of Health, annually reports most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, diet, weight) factors (cholesterol, blood pressure, glucose control) that contribute health. Statistical Update presents latest data on a range major clinical circulatory disease conditions (including congenital rhythm disorders, subclinical atherosclerosis, coronary failure, valvular venous peripheral artery disease) associated outcomes quality care, procedures, economic costs).

Language: Английский

---

2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

Atherosclerosis, Journal Year: 2019, Volume and Issue: 290, P. 140 - 205

Published: Aug. 31, 2019

Language: Английский

---

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease

Journal of the American College of Cardiology, Journal Year: 2019, Volume and Issue: 74(10), P. e177 - e232

Published: March 18, 2019

Language: Английский

---

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary

Journal of the American College of Cardiology, Journal Year: 2019, Volume and Issue: 74(10), P. 1376 - 1414

Published: March 18, 2019

Language: Английский

---

Statin Toxicity

Circulation Research, Journal Year: 2019, Volume and Issue: 124(2), P. 328 - 350

Published: Jan. 17, 2019

There is now overwhelming evidence to support lowering LDL-c (low-density lipoprotein cholesterol) reduce cardiovascular morbidity and mortality. Statins are a class of drugs frequently prescribed lower cholesterol. However, in spite their wide-spread use, discontinuation nonadherence remains major gap both the primary secondary prevention atherosclerotic disease. The reason for statin because development statin-associated muscle symptoms, but range other statin-induced side effects also exist. Although mechanisms behind these have not been fully elucidated, there an urgent need identify those at increased risk developing as well provide alternative treatment strategies. In this article, we review clinical importance toxicity focus on evaluation management symptoms.

Language: Английский

---

A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia

JAMA Cardiology, Journal Year: 2020, Volume and Issue: 5(5), P. 540 - 540

Published: Feb. 26, 2020

Low-density lipoprotein cholesterol (LDL-C), a key cardiovascular disease marker, is often estimated by the Friedewald or Martin equation, but calculating LDL-C less accurate in patients with low level hypertriglyceridemia (triglyceride [TG] levels ≥400 mg/dL).To design more equation for and/or hypertriglyceridemia.Data on and other lipid measures from 8656 seen at National Institutes of Health Clinical Center between January 1, 1976, June 2, 1999, were analyzed β-quantification reference method (18 715 test results) randomly divided into equally sized training validation data sets. Using TG non-high-density as independent variables, multiple least squares regression was used to develop an very low-density cholesterol, which then second LDL-C. Equations tested against internal set external sets either results (n = 28 891) direct 252 888). Statistical analysis performed August 7, 2018, July 18, 2019.Concordance calculated measured β-quantification, assessed various accuracy (correlation coefficient [R2], root mean square error [RMSE], absolute difference [MAD]), percentage misclassified treatment thresholds 70, 100, 190 mg/dL.Compared new than equations (slope, 0.964; RMSE 15.2 mg/dL; R2 0.9648; vs equation: slope, 1.056; 32 0.8808; 0.945; 25.7 0.9022), particularly (MAD 24.9 MAD 56.4 44.8 mg/dL). The calculates up 800 mg/dL accurately does 400 associated 35% fewer misclassifications when (TG levels, 400-800 mg/dL) categorized different groups.The can be readily implemented clinical laboratories no additional costs compared standard panel. It will allow calculation ≤800 thus should improve use risk management.

Language: Английский

---

Statin therapy increases lipoprotein(a) levels

European Heart Journal, Journal Year: 2019, Volume and Issue: 41(24), P. 2275 - 2284

Published: April 27, 2019

Lipoprotein(a) [Lp(a)] is elevated in 20-30% of people. This study aimed to assess the effect statins on Lp(a) levels.This subject-level meta-analysis includes 5256 patients (1371 placebo and 3885 statin) from six randomized trials, three statin-vs.-placebo statin-vs.-statin with pre- on-treatment (4-104 weeks) levels. Statins included atorvastatin 10 mg/day 80 mg/day, pravastatin 40 rosuvastatin pitavastatin 2 mg/day. levels were measured same validated assay. The primary analysis based log-transformed data. In pooled analysis, ratio geometric means [95% confidence interval (CI)] for statin 1.11 (1.07-1.14) (P < 0.0001), >1 indicating a higher increase baseline vs. placebo. mean percent change ranged 8.5% 19.6% groups -0.4% -2.3% groups. (95% CI) 1.09 (1.05-1.14) 0.0001). 11.6% 20.4% group 18.7% 24.2% group. Incubation HepG2 hepatocytes showed an expression LPA mRNA apolipoprotein(a) protein.This reveals that significantly plasma Elevations post-statin therapy should be studied effects residual cardiovascular risk.

Language: Английский

---